8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

8.2.1. Cytotoxic medicines

Methotrexate

Essential medicine status

ATC codes: L01BA01

Indication

Lymphoid leukaemia, not elsewhere classified

ICD11 code: 2C03.3

INN

Methotrexate

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Oral > Solid: 2.5 mg (as sodium salt)

EML status history

First added in 2015 (TRS 994)

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions
Read more about patents.

Tags

Cancer

Wikipedia

Methotrexate

DrugBank

Methotrexate

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methotrexate on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.